JP2023533768A5 - - Google Patents

Info

Publication number
JP2023533768A5
JP2023533768A5 JP2023501609A JP2023501609A JP2023533768A5 JP 2023533768 A5 JP2023533768 A5 JP 2023533768A5 JP 2023501609 A JP2023501609 A JP 2023501609A JP 2023501609 A JP2023501609 A JP 2023501609A JP 2023533768 A5 JP2023533768 A5 JP 2023533768A5
Authority
JP
Japan
Prior art keywords
specific binding
binding molecule
fragment
nucleic acid
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023501609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533768A (ja
JP7796719B2 (ja
Filing date
Publication date
Priority claimed from GBGB2010652.2A external-priority patent/GB202010652D0/en
Application filed filed Critical
Publication of JP2023533768A publication Critical patent/JP2023533768A/ja
Publication of JP2023533768A5 publication Critical patent/JP2023533768A5/ja
Application granted granted Critical
Publication of JP7796719B2 publication Critical patent/JP7796719B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023501609A 2020-07-10 2021-07-09 抗タウ抗体 Active JP7796719B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies
GB2010652.2 2020-07-10
PCT/EP2021/069160 WO2022008719A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies

Publications (3)

Publication Number Publication Date
JP2023533768A JP2023533768A (ja) 2023-08-04
JP2023533768A5 true JP2023533768A5 (https=) 2024-05-09
JP7796719B2 JP7796719B2 (ja) 2026-01-09

Family

ID=72140057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501609A Active JP7796719B2 (ja) 2020-07-10 2021-07-09 抗タウ抗体

Country Status (10)

Country Link
US (1) US20230257452A1 (https=)
EP (1) EP4178980A1 (https=)
JP (1) JP7796719B2 (https=)
KR (1) KR20230038721A (https=)
CN (1) CN116194479A (https=)
AU (1) AU2021306653A1 (https=)
CA (1) CA3185175A1 (https=)
GB (1) GB202010652D0 (https=)
TW (1) TWI912331B (https=)
WO (1) WO2022008719A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250147051A1 (en) * 2022-01-12 2025-05-08 Gtinvent Limited Method for detecting a tau protein in a saliva sample
KR20240134175A (ko) * 2022-01-12 2024-09-06 지틴벤트 리미티드 샘플에서 타우(tau) 단백질 단편을 검출하기 위한 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
WO2007110630A1 (en) 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
CA2896066C (en) * 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
UA128383C2 (uk) * 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
EP3601337A1 (en) * 2017-03-28 2020-02-05 Genentech, Inc. Methods of treating neurodegenerative diseases
US20250147051A1 (en) * 2022-01-12 2025-05-08 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Similar Documents

Publication Publication Date Title
JP2018524001A5 (https=)
NZ748983A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP2022541539A5 (https=)
JP2016503065A5 (https=)
JP2018531580A5 (https=)
RU2019118922A (ru) Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка
JP7109467B2 (ja) タウに特異的に結合する結合分子
JP2023533768A5 (https=)
JP2013524774A5 (https=)
RU2015141418A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2021524267A5 (https=)
JP2020513804A5 (https=)
JP2018505651A5 (https=)
IL266911B2 (en) Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss
JP2013525266A5 (https=)
JP2020529473A5 (https=)
JP2023071956A5 (https=)
FI3303386T3 (fi) Tau-vasta-aineita ja käyttömenetelmiä
JP2013500940A5 (https=)
JP2018535650A5 (https=)
JP2018516853A5 (https=)
US20220273779A1 (en) Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
CN115461364A (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
JP2017532288A5 (https=)
Lindberg et al. A truncated and dimeric format of an affibody library on bacteria enables FACS‐mediated isolation of amyloid‐beta aggregation inhibitors with subnanomolar affinity